Bristol Myers Squibb Co 8-K, filed Feb 10, 2021
Bristol Myers Squibb Co (BMY)
8-K
2021-02-10
For: 2021-02-10
View Original
Added on
April 02, 2026
About this 8-K
Bristol Myers Squibb Co filed this 8-K on February 10, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 10, 2021
(Exact Name of Registrant as Specified in its Charter)
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number) |
(IRS Employer Identification Number)
|
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (212 ) 546-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On February 10, 2021, each of Dr. Vicki Sato, Mr. Robert Bertolini and Mr. Matthew Emmens notified Bristol-Myers Squibb Company that they will not stand for re-election to the Board of Directors at the 2021 Annual Meeting of
Shareholders. The Board also set the number of directors at eleven, effective as of the 2021 Annual Meeting of Shareholders, which is expected to be held on
May 4, 2021.
|
(d) Exhibits
|
||
|
The following exhibit is included as part of this Current Report on Form 8-K:
|
||
|
Exhibit
No. |
|
Description
|
|
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
|
EXHIBIT INDEX
|
Exhibit
No. |
|
Description
|
|
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
BRISTOL-MYERS SQUIBB COMPANY
|
||
|
Dated: February 10, 2021
|
By:
|
/s/Katherine R. Kelly
|
|
Name:
|
Katherine R. Kelly
|
|
|
Title:
|
Corporate Secretary
|
|